Transcatheter renal sympathetic denervation for resistant arterial hypertension: When sham brings shame?

Journal of Endovascular Therapy

Volumn 21, Issue 2, 2014, Pages 197-201

  Biondi Zoccai, Giuseppe ^a   Peruzzi, Mariangela ^a   Giordano, Arturo ^b,c   Frati, Giacomo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Presidio Ospedaliero Pineta Grande   (Italy)

^c Unit of Hemodynamics Casa di Salute Santa Lucia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

ADRENERGIC SYSTEM; BLOOD PRESSURE REGULATION; HUMAN; HYPERTENSION; KIDNEY DENERVATION; MEDICAL LITERATURE; NOTE; PLACEBO EFFECT; PRIORITY JOURNAL; RESISTANT HYPERTENSION; SHAM PROCEDURE; TRANSCATHETER RENAL SYMPATHETIC DENERVATION; BLOOD PRESSURE; CATHETER ABLATION; FEMALE; INNERVATION; RENAL ARTERY; RENAL ARTERY OBSTRUCTION; SYMPATHECTOMY;

BLOOD PRESSURE; CATHETER ABLATION; FEMALE; HUMANS; HYPERTENSION; RENAL ARTERY; RENAL ARTERY OBSTRUCTION; SYMPATHECTOMY;

EID: 84899420630     PISSN: 15266028     EISSN: 15451550     Source Type: Journal    
DOI: 10.1583/13-4566/4574C1.1     Document Type: Note

References (22)

1. Merriam-Webster Online Dictionary. Available at: http://www.merriam- webster.com/dictionary/. Last accessed on January 22, 2014.
2. Mahfoud F, Lüscher TF, Andersson B, et al.; European Society of Cardiology. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J. 2013;34:2149-2157.
3. Biondi-Zoccai G, Peruzzi M, Cavarretta E, et al. Renal sympathetic denervation: from bench to bedside or the other way around? Transl Med. 2013;3:e113.
4. Krum H, Schlaich MP, Böhm M, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2013 Nov 6 [Epub ahead of print].
5. Esler MD, Krum H, Sobotka PA, et al.; Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903-1909.
6. Prochnau D, Lucas N, Kuehnert H, et al. Catheter-based renal denervation for drug-resistant hypertension by using a standard electrophysiology catheter. EuroIntervention. 2012;7:1077-1080.
7. Giordano A, Polimeno M, Messina S, et al. Transcatheter renal sympathetic denervation despite angiographically significant proximal stenosis: proof of concept from a case report. Int J Cardiol. 2014 Jan 10 [Epub ahead of print].
8. Ierna S, Biondi-Zoccai G, Bachis C, et al. Transcatheter renal sympathetic ablation for resistant hypertension: in vivo insights in humans from optical coherence tomography. Int J Cardiol. 2013;165:e35-37.
9. Templin C, Jaguszewski M, Ghadri JR, et al. Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: pre- and post-procedural comparison with the Simplicity catheter system and the EnligHTN multi-electrode renal denervation catheter. Eur Heart J. 2013;34:2141-2148.
10. Bausback Y, Friedenberger J, Hertting K, et al. Renal denervation for hypertension refractory to renal artery stenting. J Endovasc Ther. 2014;21:181-190.
11. Cooper CJ, Murphy TP, Cutlip DE, et al.; CORAL Investigators. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med. 2014;370:13-22.
12. Shetty R, Biondi-Zoccai GG, Abbate A, et al. Percutaneous renal artery intervention versus medical therapy in patients with renal artery stenosis: a meta-analysis. EuroIntervention. 2011;7:844-851.
13. Versaci F, Trivisonno A, Olivieri C, et al. Is an abnormal vascular response after renal sympathetic denervation predictive of permanent damage? An unusual case of late renal artery stenosis after energy delivery. J Endovasc Ther. 2014;21:191-196.
14. Kandzari DE, Bhatt DL, Sobotka PA, et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012;35:528-535.
15. O'Riordan M. Renal denervation fails in SYMPLICITY HTN-3. Available at: http://www.medscape.com/viewarticle/818938. Last accessed on January 22, 2014.
16. Shang A, Huwiler-Müntener K, Nartey L, et al. Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. Lancet. 2005;366:726-732. (Pubitemid 41207234)
17. Kaptchuk TJ, Stason WB, Davis RB, et al. Sham device v inert pill: randomised controlled trial of two placebo treatments. BMJ. 2006;332:391-397.
18. Miller FG. The enduring legacy of sham-controlled trials of internal mammary artery ligation. Prog Cardiovasc Dis. 2012;55:246-250.
19. Leon MB, Kornowski R, Downey WE, et al. A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol. 2005;46:1812-1819. (Pubitemid 41579801)
20. Rana JS, Mannam A, Donnell-Fink L, et al. Longevity of the placebo effect in the therapeutic angiogenesis and laser myocardial revascularization trials in patients with coronary heart disease. Am J Cardiol. 2005;95:1456-1459. (Pubitemid 40824767)
21. Galton F. Regression towards mediocrity in hereditary stature. J Anthropol Inst. 1886;15:246-263.
22. Rück A, Sylvén C. "Improvement" in the placebo group could be due to regression to the mean as well as to sociobiologic factors. Am J Cardiol. 2006;97:152-153. (Pubitemid 41828143)